Explore ViiV Healthcare

I am a
... looking for

ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

22 abstracts related to HIV treatment and prevention to be presented at major international HIV conference

London UK, 20 July, 2017 ‑ ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting 22 abstracts at the annual conference of the International AIDS Society (IAS) 23–26 July, 2017, Paris, France.

John C. Pottage Jr, Chief Scientific and Medical Officer at ViiV Healthcare, commented: “People living with HIV, and their healthcare providers, continue to look for improvements in areas related to their long-term care, such as tolerability, safety, dosing schedules, drug interactions and convenience. The data we’re sharing at IAS this year demonstrate our R&D focus on patient-centred care, with a clear drive to find new treatment regimens, new ways to deliver HIV treatments and entirely new molecules to treat and prevent HIV.” 

While significant progress has been made in tackling the global HIV epidemic, it remains a substantial public health challenge, as 2.1 million people were newly infected in 2014 and more than 36 million people live with HIV worldwide.[i] Data to be presented at IAS support ViiV Healthcare’s commitment to delivering advances in treatment and prevention options for people living with HIV (PLHIV). Key data highlights include:

  • Phase III data comparing a dolutegravir-based regimen against lopinavir/ritonavir-based regimens in patients failing first-line therapy in resource-limited settings (DAWNING)
  • A sub-study of SWORD 1 & 2: effect of switching from TDF-based regimens to dolutegravir and rilpivirine on bone mineral density and bone turnover markers
  • Longer-term (96-week) safety and efficacy data from a phase II study of a long-acting, two-drug regimen including cabotegravir and rilpivirine (LATTE-2)
  • Safety, efficacy and effects on lipid profiles of switching from a boosted protease-inhibitor-based regimen to dolutegravir-based regimen in HIV patients with high CV risk (NEAT 022)
  • Phase II data from a safety and acceptability study of long-acting, injectable, cabotegravir in HIV-uninfected men and women (HPTN 077)
  • Phase II safety and efficacy data for a two-drug regimen of dolutegravir and lamivudine in treatment-naïve patients in high- and low-baseline viral load (ACTG 5353)
  • Results from an international survey of PLHIV to explore the impact of living with an HIV diagnosis on quality of life, outlook and aspirations

These data cover a wide range of important areas in HIV research, such as:

  • Safety and efficacy in diverse populations including treatment-naïve, treatment-experienced individuals, paediatric patients and women living with HIV who are also pregnant.    
  • Quantitative and qualitative research into the lives of PLHIV, and their needs and expectations.

The breadth of this research is a result of ViiV Healthcare’s holistic approach to innovation and dedication to advancing options to help lessen the lifetime burden of HIV therapy on the lives of PLHIV and to reduce the chance of infection altogether.

Accepted Abstracts

Dolutegravir

Abstract
Title
Lead Author
Type
Location
/Time
MOPEB0283
Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR)
V. Vannappagari
Poster Exhibition
Poster
Exhibition
Area 
Monday,
24 July
MOPEC0609
Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir
C. Thorne
Poster Exhibition
Poster
Exhibition
Area 
Monday,
24 July
MOPEB0287
Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV-naive patients: 96 week results of the PADDLE trial
M. I. Figueroa
Poster Exhibition
Poster
Exhibition
Area 
Monday
24, July
TUPDB0205LB
Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF-containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks
G. McComsey
Poster Discussion Abstract
Havana
Amphitheater 
Tuesday,
25 July 13:00
TUAB0102
Switching from a boosted protease inhibitor (PI/r)-based regimen to a dolutegravir regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years is non-inferior and decreases lipids
J. M. Gatell
Oral Abstract
Le Grand Amphithéâtre 
Tuesday 25, July 14:45
TUAB0105LB
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study M. Aboud
Oral Abstract
Le Grand Amphithéâtre 
Tuesday 25, July 15:45
MOAB0103
ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/mL
B. O. Taiwo
Oral Abstract
Le Grand Amphithéâtre 
Monday, 24
July  11:30
WEPEB0573
Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA® observational database
F. Carpio
Poster Exhibition
Poster
Exhibition Area 
Wednesday, 26 July

Cabotegravir

Abstract
Title
Lead Author
Type
Location/Time
MOAX0205LB
Safety and efficacy of long-acting CAB and RPV as two-drug IM maintenance therapy: LATTE-2 week 96 results J. Eron
Oral Abstract
Blue Amphitheater Monday, 24 July 12:00
TUAC0106LB
Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected women and men: HPTN 077
R. Landovitz
Oral Abstract
Blue Amphitheater Tuesday, 25 July 12:15

Fostemsavir

Abstract
Title
Lead Author
Type
Location/Time
MOPEB0339
The effect of fostemsavir on the pharmacokinetics of a combined oral contraceptive (OC) containing ethinyl estradiol (EE) and norethindrone (NE) in healthy female subjects
M. Magee
Poster Exhibition
Poster Exhibition Area Monday, 24 July 
MOPEB0338
The effect of fostemsavir on methadone and buprenorphine pharmacokinetics
H. Sevinsky
Poster Exhibition
Poster Exhibition Area Monday, 24 July 

Abacavir

Abstract
Title
Lead Author
Type
Location/Time
WEPEB0542
Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA® Observational Database K. Mounzer
Poster Exhibition
Poster Exhibition Area Wednesday, 26 July

Maraviroc

Abstract
Title
Lead Author
Type
Location/Time
TUPEB0435
Longer-term safety of maraviroc in paediatric patients with R5 HIV: follow-up data from study A4001031 C. Giaquinto
Poster Exhibition
Poster Exhibition Area Tuesday, 25 July
TUPEB0433
Maraviroc pharmacokinetics and dosing recommendations in CCR5-tropic HIV-1-infected children aged 2 to <18 years
M. Vourvahis
Poster Exhibition
Poster Exhibition Area Tuesday, 25 July
TUPEB0432
Pharmacokinetic (PK) modelling and simulation to support weight-based dosing of maraviroc (MVC) in paediatric subjects when co-administered with potent CYP3A inhibitors L. McFadyen
Poster Exhibition
Poster Exhibition Area Tuesday, 25 July

GSK3532795/BMS-955176

Abstract
Title
Lead Author
Type
Location/
Time
MOPEB0347
Resistance profile of GSK3532795
I. Dicker
Poster Exhibition
Poster Exhibition Area 
Monday, 24 July
TULBPEB21
Safety, efficacy, and dose-response of GSK3532795/BMS-955176 plus tenofovir/emtricitabine (TDF/FTC) in treatment-naïve (TN) HIV-1-infected adults: week 24 primary analysis J. Morales-Ramirez
Poster Exhibition
Poster Exhibition Area 
Tuesday, 25 July
WEPEB0540
An analysis of neurologic and psychiatric adverse events of subjects receiving the investigational HIV-1 maturation inhibitor (MI) GSK3532795/BMS-955176 J. Gan
Poster Exhibition
Poster Exhibition Area Wednesday, 26 Jul

Other/Non-Product Related

Abstract
Title
Lead Author
Type
Location/Time
MOPEB0274
Atypical mutations for RAL resistant clinical isolates, and associated integrase strand transfer inhibitor susceptibility with public algorithms M. Underwood
Poster Exhibition
Poster Exhibition Area Monday, 24 July
WEPED1423
Experience of living with HIV: diagnosis & disclosure - findings from the Positive Perspectives study A. Murungi
Poster Exhibition
Poster Exhibition Area Monday, 24 July
WEAA0203
Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence
M. Mavigner
Oral Abstract
Maillot Room Wednesday, 26 July 17:00

[i] UNAIDS. Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet Last accessed July 2017